<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019797</url>
  </required_header>
  <id_info>
    <org_study_id>Desflurane</org_study_id>
    <nct_id>NCT02019797</nct_id>
  </id_info>
  <brief_title>Desflurane-induced Myocardial Protection</brief_title>
  <official_title>Desflurane-induced Myocardial Protection in Aortic Valve Surgery: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobuyuki Katori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Keio University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study examines pharmacological preconditioning and post conditioning of desflurane by
      comparing cardiac troponin release in patients receiving either desflurane or propofol for
      the aortic valve surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass are
      included in the study. Patients are assigned to desflurane group (Des) or propofol group
      (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and
      cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched
      to a total intravenous anesthesia (TIVA) with propofol. Prop receives a TIVA during the
      surgery. All patients receive a continuous infusion of remifentanil. Biomarker of myocardial
      damage troponin I is examined at 4 points; T1: after the induction of anesthesia, T2: arrival
      at ICU, T3: 12 hours after the ICU arrival, T4: 24 hours after the ICU arrival, T5: third
      post operative day (3POD).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Troponin I</measure>
    <time_frame>up to 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay, Length of hospital stay</measure>
    <time_frame>up to 2 months after the surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desflurane inhalation at 1-2 MAC during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-8 mg/kg/hr infusion during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.</description>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>SUPRANE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for aortic valve replacement with use of cardiopulmonary bypass.

        Exclusion Criteria:

          -  Patients younger than 20 years old.

          -  Recent myocardial infarction (within 1 year).

          -  Renal dysfunction (GFR less than 50ml/min).

          -  Known allergy to study drugs including propofol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Makoto Suematsu, M.D., Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Keio University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nobuyuki Katori, M.D.</last_name>
    <phone>81-3-3353-1211</phone>
    <phone_ext>61608</phone_ext>
    <email>nbyk@a5.keio.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroshi Morisaki, M.D.</last_name>
    <phone>81-3-3353-1211</phone>
    <phone_ext>61608</phone_ext>
    <email>morisaki@z8.keio.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nobuyuki Katori, M.D.</last_name>
      <phone>81-3-3353-1211</phone>
      <phone_ext>61608</phone_ext>
      <email>nbyk@a5.keio.jp</email>
    </contact>
    <contact_backup>
      <last_name>Hiroshi Morisaki, M.D.</last_name>
      <phone>81-3-3353-1211</phone>
      <phone_ext>61608</phone_ext>
      <email>morisaki@z8.keio.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Hiroshi Morisaki, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nobuyuki Katori, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Keio University</investigator_affiliation>
    <investigator_full_name>Nobuyuki Katori</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>aortic valve replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

